Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation

Omer Jamy; Raquel Innis-Shelton; Susan Bal; Ravi Paluri; Donna Salzman; Antonio Di Stasi; Luciano Costa; Ruby Meredith; Lawrence Lamb; Kentaro Minagawa; Shin Mineishi; Ayman Saad

doi:10.1002/ajh.26296

Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation

Omer Jamy, Raquel Innis-Shelton, Susan Bal, Ravi Paluri, Donna Salzman, Antonio Di Stasi, Luciano Costa, Ruby Meredith, Lawrence Lamb, Kentaro Minagawa, Shin Mineishi, Ayman Saad

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	E396-E398
Journal	American Journal of Hematology
Volume	96
Issue number	10
DOIs	https://doi.org/10.1002/ajh.26296
State	Published - Oct 1 2021

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1002/ajh.26296

Cite this

Jamy, O., Innis-Shelton, R., Bal, S., Paluri, R., Salzman, D., Di Stasi, A., Costa, L., Meredith, R., Lamb, L., Minagawa, K., Mineishi, S., & Saad, A. (2021). Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation. American Journal of Hematology, 96(10), E396-E398. https://doi.org/10.1002/ajh.26296

@article{8c896174b3044021bcd4dda0c812b569,

title = "Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation",

author = "Omer Jamy and Raquel Innis-Shelton and Susan Bal and Ravi Paluri and Donna Salzman and {Di Stasi}, Antonio and Luciano Costa and Ruby Meredith and Lawrence Lamb and Kentaro Minagawa and Shin Mineishi and Ayman Saad",

year = "2021",

month = oct,

day = "1",

doi = "10.1002/ajh.26296",

language = "English (US)",

volume = "96",

pages = "E396--E398",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Jamy, O, Innis-Shelton, R, Bal, S, Paluri, R, Salzman, D, Di Stasi, A, Costa, L, Meredith, R, Lamb, L, Minagawa, K , Mineishi, S & Saad, A 2021, 'Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation', American Journal of Hematology, vol. 96, no. 10, pp. E396-E398. https://doi.org/10.1002/ajh.26296

Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation. / Jamy, Omer; Innis-Shelton, Raquel; Bal, Susan et al.
In: American Journal of Hematology, Vol. 96, No. 10, 01.10.2021, p. E396-E398.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation

AU - Jamy, Omer

AU - Innis-Shelton, Raquel

AU - Bal, Susan

AU - Paluri, Ravi

AU - Salzman, Donna

AU - Di Stasi, Antonio

AU - Costa, Luciano

AU - Meredith, Ruby

AU - Lamb, Lawrence

AU - Minagawa, Kentaro

AU - Mineishi, Shin

AU - Saad, Ayman

PY - 2021/10/1

Y1 - 2021/10/1

UR - http://www.scopus.com/inward/record.url?scp=85111625809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111625809&partnerID=8YFLogxK

U2 - 10.1002/ajh.26296

DO - 10.1002/ajh.26296

M3 - Letter

C2 - 34288026

AN - SCOPUS:85111625809

SN - 0361-8609

VL - 96

SP - E396-E398

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 10

ER -

Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this